Catalyst Pharmaceuticals Company Profile (NASDAQ:CPRX)

About Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals logoCatalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CPRX
  • CUSIP: N/A
  • Web: www.catalystpharma.com
Capitalization:
  • Market Cap: $233.37 million
  • Outstanding Shares: 84,554,000
Average Prices:
  • 50 Day Moving Avg: $2.56
  • 200 Day Moving Avg: $2.44
  • 52 Week Range: $0.94 - $3.20
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.04
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.40 per share
  • Price / Book: 6.90
Profitability:
  • EBITDA: ($16,440,000.00)
  • Return on Equity: -44.65%
  • Return on Assets: -42.03%
Debt:
  • Current Ratio: 19.43%
  • Quick Ratio: 19.43%
Misc:
  • Average Volume: 569,288 shs.
  • Beta: 1.59
  • Short Ratio: 5.67
 

Frequently Asked Questions for Catalyst Pharmaceuticals (NASDAQ:CPRX)

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) released its earnings results on Wednesday, August, 9th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01. View Catalyst Pharmaceuticals' Earnings History.

When will Catalyst Pharmaceuticals make its next earnings announcement?

Catalyst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Catalyst Pharmaceuticals.

Where is Catalyst Pharmaceuticals' stock going? Where will Catalyst Pharmaceuticals' stock price be in 2017?

4 brokerages have issued 1-year price objectives for Catalyst Pharmaceuticals' stock. Their predictions range from $5.00 to $6.00. On average, they anticipate Catalyst Pharmaceuticals' share price to reach $5.50 in the next year. View Analyst Ratings for Catalyst Pharmaceuticals.

Are investors shorting Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals saw a drop in short interest during the month of September. As of September 15th, there was short interest totalling 4,220,460 shares, a drop of 35.4% from the August 31st total of 6,532,907 shares. Based on an average daily volume of 856,492 shares, the short-interest ratio is currently 4.9 days. Currently, 5.9% of the shares of the stock are sold short.

Who are some of Catalyst Pharmaceuticals' key competitors?

Who are Catalyst Pharmaceuticals' key executives?

Catalyst Pharmaceuticals' management team includes the folowing people:

  • Patrick James McEnany, Chairman of the Board, President, Chief Executive Officer
  • Alicia Grande CPA, Chief Financial Officer, Vice President, Treasurer
  • Steven R. Miller Ph.D., Chief Operating Officer, Chief Scientific Officer
  • David D. Muth, Executive Vice President, Chief Commercial Officer
  • M. Douglas Winship, Vice President - Regulatory Operations
  • David J. Caponera, Vice President - Patient Advocacy & Reimbursement
  • Bernardino Mosquera M.D., Vice President - Clinical Operations
  • Charles B. O'Keeffe, Lead Independent Director
  • Gary Ingenito M.D., Chief Medical Officer
  • Richard J. Daly, Director

How do I buy Catalyst Pharmaceuticals stock?

Shares of Catalyst Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catalyst Pharmaceuticals' stock price today?

One share of Catalyst Pharmaceuticals stock can currently be purchased for approximately $2.76.


MarketBeat Community Rating for Catalyst Pharmaceuticals (NASDAQ CPRX)
Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  177 (Vote Outperform)
Underperform Votes:  68 (Vote Underperform)
Total Votes:  245
MarketBeat's community ratings are surveys of what our community members think about Catalyst Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Catalyst Pharmaceuticals (NASDAQ:CPRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.50 (99.28% upside)
Consensus Price Target History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Price Target History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Analysts' Ratings History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/5/2017SunTrust Banks, Inc.Reiterated RatingBuy$5.00HighView Rating Details
8/10/2017Roth CapitalSet Price TargetBuy$5.00LowView Rating Details
8/7/2017Piper Jaffray CompaniesSet Price TargetBuy$6.00LowView Rating Details
3/20/2017HC WainwrightReiterated RatingBuy$6.00LowView Rating Details
(Data available from 10/22/2015 forward)

Earnings

Earnings History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Earnings by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Earnings History by Quarter for Catalyst Pharmaceuticals (NASDAQ CPRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.06)N/AView Earnings Details
8/9/2017Q2 2017($0.06)($0.05)ViewListenView Earnings Details
5/10/2017Q1 2017($0.06)($0.06)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.07)($0.05)ViewN/AView Earnings Details
11/9/2016Q316($0.06)($0.05)ViewListenView Earnings Details
8/9/2016Q216($0.08)($0.06)ViewN/AView Earnings Details
5/10/2016Q116($0.07)($0.07)ViewN/AView Earnings Details
3/15/2016Q415($0.07)($0.07)ViewN/AView Earnings Details
8/10/2015Q215($0.08)($0.06)ViewListenView Earnings Details
5/11/2015Q115($0.08)($0.06)ViewN/AView Earnings Details
3/16/2015Q414($0.07)($0.06)ViewN/AView Earnings Details
11/14/2014Q314($0.06)($0.06)ViewN/AView Earnings Details
8/14/2014Q214($0.08)($0.05)ViewN/AView Earnings Details
3/19/2014Q413($0.07)($0.02)ViewN/AView Earnings Details
11/14/2013Q3($0.07)($0.07)ViewN/AView Earnings Details
8/15/2013Q213($0.07)($0.06)ViewN/AView Earnings Details
11/15/2012Q312($0.08)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Catalyst Pharmaceuticals (NASDAQ:CPRX)
2017 EPS Consensus Estimate: ($0.24)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.06)($0.06)($0.06)
Q2 20171($0.06)($0.06)($0.06)
Q3 20171($0.06)($0.06)($0.06)
Q4 20172($0.07)($0.05)($0.06)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Insider Ownership Percentage: 8.79%
Institutional Ownership Percentage: 40.10%
Insider Trades by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Insider Trades by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/5/2017Patrick J McenanyInsiderBuy20,000$2.58$51,600.00View SEC Filing  
7/12/2016Charles B O'keeffeDirectorBuy20,000$0.81$16,200.00View SEC Filing  
6/17/2016Philip H CoelhoDirectorBuy15,000$0.76$11,400.00View SEC Filing  
6/14/2016Donald A DenkhausDirectorBuy50,000$0.65$32,500.00View SEC Filing  
6/14/2016Patrick J McenanyCEOBuy105,300$0.65$68,445.00View SEC Filing  
4/26/2016Charles B O'keeffeDirectorBuy20,000$0.60$12,000.00View SEC Filing  
4/26/2016Patrick J McenanyCEOBuy50,000$0.65$32,500.00View SEC Filing  
3/17/2016Philip H CoelhoDirectorBuy10,000$1.06$10,600.00View SEC Filing  
3/16/2016Charles B O'keeffeDirectorBuy10,000$1.11$11,100.00View SEC Filing  
1/11/2016Steve MillerCOOBuy7,933$1.80$14,279.40View SEC Filing  
1/8/2016Charles B O'keeffeDirectorBuy5,000$1.94$9,700.00View SEC Filing  
1/7/2016Donald A DenkhausDirectorBuy25,000$2.03$50,750.00View SEC Filing  
12/28/2015Patrick J McenanyCEOBuy25,000$2.39$59,750.00View SEC Filing  
12/23/2015Charles B O'keeffeDirectorBuy5,000$2.41$12,050.00View SEC Filing  
11/19/2015Charles B O'keeffeDirectorBuy5,000$2.30$11,500.00View SEC Filing  
10/23/2015M Douglas WinshipVPSell22,800$3.34$76,152.00View SEC Filing  
10/1/2015Patrick J McenanyCEOBuy10,000$2.81$28,100.00View SEC Filing  
5/1/2015David D MuthEVPBuy1,700$3.20$5,440.00View SEC Filing  
4/30/2015Charles B O'keeffeDirectorBuy10,000$3.29$32,900.00View SEC Filing  
4/28/2015David D MuthEVPBuy2,000$3.55$7,100.00View SEC Filing  
4/27/2015Donald A DenkhausDirectorBuy15,000$3.71$55,650.00View SEC Filing  
4/27/2015Patrick J McenanyCEOBuy5,000$3.79$18,950.00View SEC Filing  
4/24/2015Charles B O'keeffeDirectorBuy5,000$3.80$19,000.00View SEC Filing  
3/27/2015Donald A DenkhausDirectorBuy5,000$4.17$20,850.00View SEC Filing  
1/20/2015David D MuthEVPBuy21,000$2.96$62,160.00View SEC Filing  
1/13/2015Charles B O'keeffeDirectorBuy10,000$3.00$30,000.00View SEC Filing  
1/8/2015Patrick J McenanyCEOBuy50,000$2.80$140,000.00View SEC Filing  
10/3/2014David D MuthVPBuy10,000$2.65$26,500.00View SEC Filing  
6/4/2014Steve MillerCOOBuy100,000$2.17$217,000.00View SEC Filing  
5/21/2014Patrick McenanyCEOBuy25,000$1.89$47,250.00View SEC Filing  
5/19/2014Charles O'keeffeDirectorBuy10,000$1.83$18,300.00View SEC Filing  
4/16/2014Charles O'keeffeDirectorBuy5,000$2.02$10,100.00View SEC Filing  
2/7/2014Patrick McenanyCEOBuy25,000$1.82$45,500.00View SEC Filing  
2/5/2014Charles O'keeffeDirectorBuy10,000$1.81$18,100.00View SEC Filing  
10/23/2013David S TierneyDirectorBuy8,000$2.03$16,240.00View SEC Filing  
10/21/2013Charles B O'keeffeDirectorBuy10,000$1.84$18,400.00View SEC Filing  
10/21/2013Patrick J McenanyCEOBuy50,000$1.59$79,500.00View SEC Filing  
2/19/2013Patrick J McenanyCEOBuy50,000$0.46$23,000.00View SEC Filing  
12/17/2012Patrick J McenanyCEOBuy100,000$0.45$45,000.00View SEC Filing  
12/8/2012Biomarin Pharmaceutical IncMajor ShareholderBuy5,000,000$0.75$3,750,000.00View SEC Filing  
11/15/2012Patrick J McenanyCEOBuy100,000$0.42$42,000.00View SEC Filing  
11/15/2012Philip H CoelhoDirectorBuy24,000$0.41$9,840.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Latest Headlines for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Source:
Loading headlines, please wait.

Social

Chart

Catalyst Pharmaceuticals (CPRX) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.